Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
30 avr. 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
16 avr. 2024 07h05 HE
|
Clearside Biomedical, Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
02 avr. 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18 mars 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 mars 2024 16h05 HE
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
29 févr. 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
07 févr. 2024 08h00 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to...
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
14 déc. 2023 07h05 HE
|
Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 16h05 HE
|
Clearside Biomedical, Inc.
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
08 nov. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...